Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620805 | 0.93 | NR1H2 (0.57) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL29180653 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL20031478 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL21774419 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL23963745 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL8256164 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL500506 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL14870523 | 0.92 | NR1H2 (0.60) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL24751957 | 0.90 | NR1H2 (0.58) | NR1H2HPGDUSP2SMN1; SMN2PREP | |
| SCHEMBL21135640 | 0.90 | NR1H2 (0.58) | NR1H2HPGDUSP2SMN1; SMN2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243186-A1 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024191988-A1 | 3,4-FUSED BICYCLIC PYRROLIDINE AND 3,4-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-118510765-A | Piperidinyl indole derivatives, preparation method and medical application thereof | 翰森生物有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243186-A1 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | IDO1, IDO2, TPH1 | NR1H2 2169/4885HPGD 150/4885USP2 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.